This company has been marked as potentially delisted and may not be actively trading. Vallon Pharmaceuticals (VLON) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock VLON vs. SGMT, TELO, CRVO, ASMB, SAVA, UNCY, MNOV, BMEA, ANL, and XCURShould you be buying Vallon Pharmaceuticals stock or one of its competitors? The main competitors of Vallon Pharmaceuticals include Sagimet Biosciences (SGMT), Telomir Pharmaceuticals (TELO), CervoMed (CRVO), Assembly Biosciences (ASMB), Cassava Sciences (SAVA), Unicycive Therapeutics (UNCY), MediciNova (MNOV), Biomea Fusion (BMEA), Adlai Nortye (ANL), and Exicure (XCUR). These companies are all part of the "pharmaceutical preparations" industry. Vallon Pharmaceuticals vs. Sagimet Biosciences Telomir Pharmaceuticals CervoMed Assembly Biosciences Cassava Sciences Unicycive Therapeutics MediciNova Biomea Fusion Adlai Nortye Exicure Vallon Pharmaceuticals (NASDAQ:VLON) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, community ranking, dividends, media sentiment and earnings. Is VLON or SGMT more profitable? Sagimet Biosciences' return on equity of -23.63% beat Vallon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Vallon PharmaceuticalsN/A -230.48% -124.89% Sagimet Biosciences N/A -23.63%-22.91% Do institutionals & insiders have more ownership in VLON or SGMT? 8.7% of Vallon Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are owned by institutional investors. 37.3% of Vallon Pharmaceuticals shares are owned by insiders. Comparatively, 17.6% of Sagimet Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk and volatility, VLON or SGMT? Vallon Pharmaceuticals has a beta of -1.14, indicating that its stock price is 214% less volatile than the S&P 500. Comparatively, Sagimet Biosciences has a beta of 2.4, indicating that its stock price is 140% more volatile than the S&P 500. Which has preferable valuation and earnings, VLON or SGMT? Vallon Pharmaceuticals has higher earnings, but lower revenue than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Vallon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVallon Pharmaceuticals$100K245.37-$7.02M-$0.78-2.33Sagimet Biosciences$2M60.35-$27.88M-$1.43-2.75 Does the media favor VLON or SGMT? In the previous week, Sagimet Biosciences had 3 more articles in the media than Vallon Pharmaceuticals. MarketBeat recorded 3 mentions for Sagimet Biosciences and 0 mentions for Vallon Pharmaceuticals. Sagimet Biosciences' average media sentiment score of 1.12 beat Vallon Pharmaceuticals' score of 0.00 indicating that Sagimet Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Vallon Pharmaceuticals Neutral Sagimet Biosciences Positive Does the MarketBeat Community favor VLON or SGMT? Sagimet Biosciences received 26 more outperform votes than Vallon Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Vallon Pharmaceuticals an outperform vote while only 96.43% of users gave Sagimet Biosciences an outperform vote. CompanyUnderperformOutperformVallon PharmaceuticalsOutperform Votes1100.00% Underperform VotesNo VotesSagimet BiosciencesOutperform Votes2796.43% Underperform Votes13.57% Do analysts recommend VLON or SGMT? Sagimet Biosciences has a consensus target price of $22.40, suggesting a potential upside of 469.25%. Given Sagimet Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Sagimet Biosciences is more favorable than Vallon Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vallon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Sagimet Biosciences 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 SummarySagimet Biosciences beats Vallon Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get Vallon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VLON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VLON vs. The Competition Export to ExcelMetricVallon PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.54M$6.71B$5.49B$7.95BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-2.337.3522.6218.58Price / Sales245.37241.98397.85103.49Price / CashN/A65.8538.1834.62Price / Book10.116.496.744.25Net Income-$7.02M$143.41M$3.22B$248.18M Vallon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VLONVallon PharmaceuticalsN/A$1.82+1.1%N/A+318.5%$24.54M$100,000.00-2.333SGMTSagimet Biosciences2.8248 of 5 stars$2.56+6.9%$22.40+776.7%-11.5%$78.38M$2M-1.798Gap UpTELOTelomir Pharmaceuticals2.5106 of 5 stars$2.60+2.2%$15.00+478.0%-61.5%$77.24MN/A-4.471News CoverageCRVOCervoMed3.6008 of 5 stars$8.87-4.7%$27.50+210.2%-62.7%$77.15M$7.14M-4.374ASMBAssembly Biosciences3.6577 of 5 stars$10.24+3.0%$33.00+222.3%-8.7%$76.83M$28.52M-1.52100Upcoming EarningsNews CoveragePositive NewsSAVACassava Sciences3.6331 of 5 stars$1.59+8.6%$54.50+3,338.5%-93.0%$76.57MN/A-1.1530News CoverageUNCYUnicycive Therapeutics3.7732 of 5 stars$0.62+2.3%$5.50+781.4%-41.8%$75.53M$680,000.00-0.659Short Interest ↓Positive NewsMNOVMediciNova1.889 of 5 stars$1.49+1.4%$9.00+504.0%+17.8%$73.08M$1M-6.4810Upcoming EarningsShort Interest ↓News CoverageBMEABiomea Fusion3.2811 of 5 stars$1.94+12.7%$23.91+1,133.7%-80.4%$72.82MN/A-0.4850News CoveragePositive NewsANLAdlai Nortye2.623 of 5 stars$1.94+13.5%$9.00+363.9%-86.7%$71.59M$5M0.00127Short Interest ↓News CoveragePositive NewsGap UpXCURExicure2.181 of 5 stars$11.33+0.3%N/A+1,925.2%$71.58M$500,000.00-5.4750Short Interest ↓Positive News Related Companies and Tools Related Companies SGMT Alternatives TELO Alternatives CRVO Alternatives ASMB Alternatives SAVA Alternatives UNCY Alternatives MNOV Alternatives BMEA Alternatives ANL Alternatives XCUR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VLON) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vallon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vallon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
